Section Arrow
Quote
ONC.NASDAQ
- BeOne Medicines Ltd
Quotes are at least 15-min delayed:2026/10/18 21:42 EDT
Regular Hours
Last
 369.06
-5.02 (-1.34%)
Day High 
375.9 
Prev. Close
374.08 
1-M High
376.5 
Volume 
431.21K 
Bid
369.06
Ask
369.33
Day Low
367.3045 
Open
372.57 
1-M Low
340.445 
Market Cap 
42.32B 
Currency 美元 
P/E 66.92 
%Yield -- 
10-SMA 357.62 
20-SMA 360.18 
50-SMA 359.43 
52-W High 385.22 
52-W Low 253.9475 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
5.59/9.93
Enterprise Value
43.33B
Balance Sheet
Book Value Per Share
45.74
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
5.34B
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugsin its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.